Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: From toxicogenomics to emerging biomarkers

Pharmacological Research

Volumn 64, Issue 1, 2011, Pages 25-30

  Pallet, Nicolas ^a   Djamali, Arjang ^b   Legendre, Christophe ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Biomarkers; Calcineurin inhibitors; Endoplasmic reticulum stress; Epithelial to mesenchymal transition; Nephrotoxicity; Renal transplantation

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR;

EARLY DIAGNOSIS; ENDOPLASMIC RETICULUM STRESS; EPITHELIAL MESENCHYMAL TRANSITION; HISTOPATHOLOGY; HUMAN; MOLECULAR PATHOLOGY; NEPHROTOXICITY; NONHUMAN; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REVIEW; TOXICOGENETICS;

ANIMALS; BIOLOGICAL MARKERS; CALCINEURIN; DRUG TOXICITY; HUMANS; KIDNEY DISEASES; TOXICOGENETICS;

EID: 79957749623     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.03.013     Document Type: Review

References (56)

1. Srinivas TR, Flechner SM, Poggio ED, Askar M, Goldfarb DA, Navaneethan SD, et al. Glomerular filtration rate slopes have significantly improved among renal transplants in the united states. Transplantation 2009;90:1499-505.
2. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009;9:527-35.
3. Matas AJ, Leduc R, Rush D, Cecka JM, Connett J, Fieberg A, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of can or cr: preliminary data from the dekaf study. Am J Transplant 2010;10:315-23.
4. Mannon RB, Fairchild R. Allograft fibrosis-unmasking the players at the dance. Am J Transplant 2010;10:201-2.
5. Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003;14:2980-4. (Pubitemid 37305662)
6. Rowshani AT, Scholten EM, Bemelman F, Eikmans M, Idu M, Roos-van Groningen MC, et al. No difference in degree of interstitial sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 2006;17:305-12.
7. Roos-van Groningen MC, Scholten EM, Lelieveld PM, Rowshani AT, Baelde HJ, Bajema IM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006;17:881-8.
8. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase iii study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (benefit study). Am J Transplant 2010;10:535-46.
9. Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, Rial MD, et al. Switching from calcineurin inhibitor based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase ii study. Clin J AmSoc Nephrol 2010.
10. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22:1-15. (Pubitemid 351149996)
11. Liptak P, Ivanyi B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006;2:398-404. (Pubitemid 44034190)
12. Naesens M, Kuypers D, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481-508.
13. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557-65. (Pubitemid 39097102)
14. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006;81:643-54.
15. Pallet N, Bouvier N, Bendjallabah A, Rabant M, Hertig A, Legendre C, et al. Cyclosporine-induced endoplasmic reticulum stress triggers phenotypic changes and death. Am J Transplant 2008;8:2283-96.
16. Cauduro RL, Costa C, Lhulier F, Garcia RG, Cabral RD, Goncalves LF, et al. Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin Transplant 2005;19:470-4. (Pubitemid 40990655)
17. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993;91:2144-9. (Pubitemid 23141490)
18. Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990;1:76-83.
19. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985;28:767-74. (Pubitemid 16156317)
20. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990;323:693-9. (Pubitemid 20288937)
21. Conger JD, Kim GE, Robinette JB. Effects of ang ii, eta, and txa2 receptor antagonists on cyclosporin a renal vasoconstriction.AmJ Physiol 1994;267:F443-449.
22. Darlametsos IE, Varonos DD. Role of prostanoids and endothelins in the prevention of cyclosporine-induced nephrotoxicity. Prostaglandins Leukot Essent Fatty Acids 2001;64:231-9. (Pubitemid 32619997)
23. Campistol JM, Inigo P, JimenezW,Lario S, Clesca PH, Oppenheimer F, et al. Losartan decreases plasma levels of tgf-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-9. (Pubitemid 29353172)
24. Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin ii and osteopontin. J Am Soc Nephrol 1995;6:1186-96.
25. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of tgf-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002;62:2257-63. (Pubitemid 35366184)
26. Khanna AK, Plummer MS, Hilton G, Pieper GM, Ledbetter S. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications. Circulation 2004;110:3822-9. (Pubitemid 40023981)
27. Ozdemir BH, Ozdemir FN, Demirhan B, Haberal M. Tgf-beta1 expression in renal allograft rejection and cyclosporine a toxicity. Transplantation 2005;80:1681-5. (Pubitemid 43053991)
28. Buetler TM, Cottet-Maire F, Krauskopf A, Ruegg UT. Does cyclosporin a generate free radicals? Trends Pharmacol Sci 2000;21:288-90.
29. Justo P, Lorz C, Sanz A, Egido J, Ortiz A. Intracellular mechanisms of cyclosporin a-induced tubular cell apoptosis. J Am Soc Nephrol 2003;14:3072-80. (Pubitemid 37509285)
30. Chapman J, Nankivell B. Nephrotoxicity of ciclosporin a: short-term gain, long-term pain? Nephrol Dial Transplant 2006;21:2060-3.
31. Miura Y, Satoh S, Saito M, Numakura K, Inoue T, Obara T, et al. Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. Transplantation 2010.
32. Servais A, Meas-Yedid V, Toupance O, Lebranchu Y, Thierry A, Moulin B, et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009;9:2552-60.
33. Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, et al. Calcineurin-inhibitor-free immunosuppression based on the jak inhibitor cp-690, 550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009;9:1936-45.
34. Snanoudj R, Royal V, Girardin C, Kreis H, Martinez F, Thervet E, et al. Comparison of histological lesions on ten years protocol biopsies in kidney transplant recipients with or without cyclosporine. Am J Transplant 2009;9:200.
35. Ying L, Sarwal M. In praise of arrays. Pediatr Nephrol 2009;24:1643-59, quiz 1655, 1659.
36. Xiang CC, Chen Y. Cdna microarray technology and its applications. Biotechnol Adv 2000;18:35-46. (Pubitemid 30300756)
37. Du S, Hiramatsu N, Hayakawa K, Kasai A, Okamura M, Huang T, et al. Suppression of nf-kappab by cyclosporin a and tacrolimus (fk506) via induction of the c/ebp family: implication for unfolded protein response. J Immunol 2009;182:7201-11.
38. Kitamura M. Endoplasmic reticulum stress and unfolded protein response in the kidney: janus faces. Am J Physiol Renal Physiol 2008;295:323-34.
39. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12. (Pubitemid 38020692)
40. Zhang K, Kaufman RJ. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 2004;279:25935-8. (Pubitemid 38798732)
41. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110:341-50. (Pubitemid 34847966)
42. Neilson EG. Plasticity, nuclear diapause, and a requiem for the terminal differentiation of epithelia. J Am Soc Nephrol 2007;18:1995-8. (Pubitemid 47041062)
43. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 2006;17:2992-8. (Pubitemid 44707759)
44. Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002;13:96-107. (Pubitemid 34042016)
45. Eberl T, Salvenmoser W, Rieger G, Gorny I, Heiss V, Kumpitsch B, et al. Ultrastructural analysis of human endothelial cells after hypothermic storage in organ preservation solutions. J Surg Res 1999;82:253-60. (Pubitemid 29394131)
46. Massague J. How cells read tgf-beta signals. Nat Rev Mol Cell Biol 2000;1:169-78.
47. Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine a-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol 2005;167:395-407. (Pubitemid 43026096)
48. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, et al. A selective inhibitor of eif2alpha dephosphorylation protects cells from er stress. Science 2005;307:935-9. (Pubitemid 40229232)
49. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005;115:2656-64. (Pubitemid 41434389)
50. Pallet N. Response of tubular cells to cyclosporine and sirolimus: a toxicogenomic study. Toxicol Appl Pharmacol 2008;229:184-96.
51. Han SW, Li C, Ahn KO, Lim SW, Song HG, Jang YS, et al. Prolonged endoplasmic reticulum stress induces apoptotic cell death in an experimental model of chronic cyclosporine nephropathy. Am J Nephrol 2008;28:707-14.
52. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008;86:192-9.
53. Li J, Liu B, Yan LN, Wang LL, Lau WY, Li B, et al. Microproteinuria for detecting calcineurin inhibitor-related nephrotoxicity after liver transplantation. World J Gastroenterol 2009;15:2913-7.
54. Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006;6:2937-46.
55. Hertig A, Anglicheau D, Verine J, Pallet N, Touzot M, Ancel PY, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008;19:1584-91.
56. Pallet N, Fougeray S, Beaune P, Legendre C, Thervet E, Anglicheau D. Endoplasmic reticulum stress: an unrecognized actor in solid organ transplantation. Transplantation 2009;88:605-13.